Vircell closes 2017 with excellent results and faces this year with the challenge of keeping up the growth trend.
In a year in which global economic activity continues to strengthen, Vircell has achieved a turnover of +28% versus 2016. International sales have represented 85% of the total, in line with previous years.
In this period, the international network of distributors has grown, allowing the penetration in new markets of Central and North America, and sales in key destinations for Vircell's growth strategy have been consolidated. All these efforts result in a diversified sales mix, with Asia (40%), Europe (34%), America (11%) and the Middle East (10%) as fundamental markets.
The sales structure per product line in 2017 varies slightly with respect to previous years, notably improving the positions of VirClia® (14%) and AmpliRun® (8%) as the third and fourth most sold product lines in our portfolio. We would like to highlight the important efforts made in VirClia® that have extended the panel, reaching more than 80 references this year.
The excellent results achieved in 2017 are indicative of the professionalism of our distributors and the dedication, effort and know-how of our employees who work to provide the best diagnostic solutions to our clients in all markets.
In 2018 we plan to focus our efforts on the promotion of VirClia®, as the most flexible chemiluminescence solution for the automation of infectious serology. Molecular biology continues to be one of our most important areas with the expansion of AmpliRun® in laboratories around the world and the launch of a new generation of Speed-oligo® products.